MX2024001189A - Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r. - Google Patents

Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r.

Info

Publication number
MX2024001189A
MX2024001189A MX2024001189A MX2024001189A MX2024001189A MX 2024001189 A MX2024001189 A MX 2024001189A MX 2024001189 A MX2024001189 A MX 2024001189A MX 2024001189 A MX2024001189 A MX 2024001189A MX 2024001189 A MX2024001189 A MX 2024001189A
Authority
MX
Mexico
Prior art keywords
methods
antagonist
administering
treating chronic
chronic spontaneous
Prior art date
Application number
MX2024001189A
Other languages
English (en)
Spanish (es)
Inventor
Allen Radin
Leda Mannent
Nikhil Amin
Heribert Staudinger
Elizabeth Laws
Aleksandra Stjepanovic
Naimish Patel
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Publication of MX2024001189A publication Critical patent/MX2024001189A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2024001189A 2021-07-26 2022-07-25 Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r. MX2024001189A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163225716P 2021-07-26 2021-07-26
US202163240734P 2021-09-03 2021-09-03
US202263313041P 2022-02-23 2022-02-23
EP22315049 2022-03-04
US202263353654P 2022-06-20 2022-06-20
PCT/US2022/038185 WO2023009437A1 (en) 2021-07-26 2022-07-25 Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist

Publications (1)

Publication Number Publication Date
MX2024001189A true MX2024001189A (es) 2024-02-27

Family

ID=82899210

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001189A MX2024001189A (es) 2021-07-26 2022-07-25 Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r.

Country Status (9)

Country Link
US (1) US20230146317A1 (https=)
EP (1) EP4377345A1 (https=)
JP (1) JP2024529434A (https=)
KR (1) KR20240037321A (https=)
AU (1) AU2022316939A1 (https=)
CA (1) CA3226781A1 (https=)
IL (1) IL310362A (https=)
MX (1) MX2024001189A (https=)
WO (1) WO2023009437A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
WO2025088063A2 (en) * 2023-10-24 2025-05-01 Sanofi Systems and methods for monitoring a medicament dosing schedule
KR20250118250A (ko) * 2024-01-26 2025-08-06 연세대학교 산학협력단 식물에서 발현된 항-IL-4Rα 항체의 항원결합 단편 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
TWI633891B (zh) * 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
CA3132587A1 (en) * 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy

Also Published As

Publication number Publication date
EP4377345A1 (en) 2024-06-05
KR20240037321A (ko) 2024-03-21
CA3226781A1 (en) 2023-02-02
IL310362A (en) 2024-03-01
US20230146317A1 (en) 2023-05-11
AU2022316939A1 (en) 2024-03-07
JP2024529434A (ja) 2024-08-06
WO2023009437A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
MX2024001189A (es) Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r.
AU2014284235B2 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX2022014440A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
JO3559B1 (ar) جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
MX2022011730A (es) Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.
MX2021013427A (es) Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
WO2015006571A8 (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
MX2025011152A (es) Metodos para el tratamiento de la enfermedad pulmonar obstructiva cronica (epoc) mediante la administracion de un antagonista de il-4r
PH12013500890A1 (en) Methods of treating rheumatoid arthritis using il-17 antagonists
MX2022001247A (es) Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r.
MX2017006286A (es) Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r.
MY163953A (en) Methods of inhibiting tumor growth by antagonizing il-6 receptor
MX368508B (es) Benralizumab para usarse en la reducción de la tasa de exacerbación de asma.
MX2025005113A (es) Metodos para tratar la dermatitis de manos y pies mediante la administracion de un antagonista de il-4r
MX2024002072A (es) Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.
MX2022007958A (es) Metodos para tratar o prevenir el asma alergica mediante la administracion de un antagonista de il-33 y/o un antagonista de il-4r.
EP4276108A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
MX2024004762A (es) Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r.
MX2025011114A (es) Metodos para el tratamiento de la gastroenteritis eosinofilica mediante la administracion de un antagonista de il-4r
MX2023001199A (es) Antagonistas de receptor nk para pacientes con cancer.
MX2022005718A (es) Anticuerpos tmem219 y usos terapeuticos de los mismos.
MX2022001411A (es) Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5.